Myofascial Pelvic PainNCT07181447
NIRS for the Diagnosis of Myofascial Pelvic Pain
An observational study of Myofascial Pelvic Pain, run by University of California, Los Angeles at 1 site in United States.
Trial summary
Myofascial Pelvic Pain (MPP) is an often-misdiagnosed condition affecting up to 26% of women during their lives and imposing enormous costs on national health care systems. It frequently involves comorbidities such as bladder, bowel, and sexual dysfunction. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Myofascial Pelvic Pain
- What is being tested?
- Pelvic Floor Muscle Assessment by Near-Infrared Spectroscopy
- How many people
- 110 participants
- Where
- 1 siteUnited States
- Study dates
- 23 Jan 2025to 1 Sep 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: The control subjects (cohort 1) will be adult 18 (>18 years of age) who lack pelvic pain or other genitourinary symptoms. The MPP cohort (cohort 2) will consist of adult women >18 years of age with pelvic floor muscle pain or tender points.
Who may be able to join
- Women between 18 and 100 years of age
- Pelvic pain for more than 6 months duration
- Report an average daily pain intensity score of at least 4 (on a 0 to 10 scale)
- Palpable trigger/tender points in internal pelvic floor muscles on standardized myofascial pelvic floor exam
- Willing to refrain from new clinical treatments that may affect pain during the study period
Who cannot join
- Inability to participate in clinic visits
- Prior invasive pelvic procedures for pain (e.g., prior pelvic surgery, sacral neuromodulation, intradetrusor Botox®)
- Active UTI or vaginal infection
- Pregnancy, childbirth during the previous 12 months, currently planning pregnancy
- Illicit Drug addiction/regular use of controlled substances
- Malignancy or other serious medical condition (e.g., poorly controlled diabetes [HgA1c > 8], neurologic or rheumatic disease)
Show all 11Show fewer
- Diagnosed with an alternate cause of pelvic pain (e.g., interstitial cystitis, vestibulodynia, vulvar dermatoses dysmenorrhea)
- Urinary retention
- Greater than stage 3 pelvic organ prolapse
- Indwelling vaginal devices (e.g., pessary, contraceptive ring)
- Inability to sign an informed consent, fill out questionnaires, or complete study interviews
Trial locations and contacts
1 site in 1 country.
United States1 site
UCLA Center for Women's Pelvic Health
Los Angeles, California, 90095
About this study
Official title: Quantitative Assessment of Pelvic Floor Muscle Fitness in Myofascial Pelvic Pain
Myofascial Pelvic Pain (MPP) is an often-misdiagnosed condition affecting up to 26% of women during their lives and imposing enormous costs on national health care systems. It frequently involves comorbidities such as bladder, bowel, and sexual dysfunction. There are no quantitative measures that adequately guide the physician and accurate diagnosis typically requires an internal examination by a tertiary specialist.
This study will develop and test an instrument to establish a normal range for near infrared spectroscopy (NIRS) optical changes associate with pelvic floor exercise in adult women based on the test-to test (intra-day) reliability of oxygen kinetics related to contraction of the pelvic floor muscle.
Read more
We will establish the relationship between the quantitative NIRS data, the condition of Myofascial pelvic musculature and the symptomatology of MPP and related comorbidities. We will also evaluate prospectively the effectiveness of these data in predicting effective treatment modalities. Finally, we will optimize a training regime for non-specialists to allow this technique to be used in a variety of settings.
The development of this device and validation of its relevance to diagnosis and treatment of MPP will provide effective care sooner and at a lower cost than current procedures. It will also reduce inequities in the availability of care to underserved populations by providing an inexpensive, reliable and easily available method for a variety of providers to address MPP.
Read the detailed description
DETAILED DESCRIPTION Introduction. Myofascial pelvic pain (MPP) is the predominant underlying cause in 60-90% of women with chronic pelvic pain. MPP can be debilitating, and is often associated with bladder, bowel, and sexual dysfunction. MPP can be debilitating, leading to social withdrawal, loss of productivity, impaired relationships, and psychological comorbidities. Despite the high prevalence, myofascial pain is often overlooked by first-line healthcare providers; most providers, including gynecologic and urologic specialists, lack the knowledge or experience to even identify MPP. Unfortunately, there are currently no widely accepted measures to quantify muscular fitness or dynamic function of the pelvic floor. Improved recognition of MPP needs objective, reproducible, and quantifiable assessments of PFM fitness, to differentiate between forms of myofascial dysfunction and correlate those patterns with different symptoms. Improved recognition of MPP needs objective, reproducible, and quantifiable assessments of PFM fitness, to facilitate improvements in the recognition and diagnosis of MPP.
Objective: This trial will use optical technology (near infrared spectroscopy) to provide novel imaging and physiologic measures relevant to the PFM for the diagnostic evaluation of MPP.
Primary Purpose: Diagnostics Subject Recruitment: Healthy controls, who must lack pelvic pain, bowel disturbances, urinary symptoms, or sexual dysfunction, will be recruited from the community through online and targeted advertisements in gynecology and primary clinics. IRB approval for these studies is already in place, and we have already begun recruitment of control volunteers. Subjects with MPP, defined by pelvic floor myofascial pain in the absence of other identifiable pain generators, will be recruited from the UCLA Center for Women's Pelvic Health.24 MPP subjects meeting inclusion/exclusion criteria will be approached for enrollment prior to treatment assignment. Baseline demographics and clinical data, including age, height, weight, comorbidities, past surgeries, and medications, including hormones, will be self-reported at enrollment through a questionnaire on REDCap.
Vaginal NIRS-based Pelvic Floor Assessment: An 8-channel, multipoint vaginal NIRS interface miniaturized into a tampon-sized instrument, capable of measuring regional changes in pelvic floor muscle oxygenation in different quadrants and muscle depths, will assess oxygenation and hemodynamic parameters in the pelvic floor muscles. The NIRS sensor, housed in a sterile, single use, disposable child size speculum and placed within a sterile cover, will be inserted in the vagina. The participant will then complete two rounds of the same standardized series of contractions: a series of three maximal voluntary contractions (MVC) and one sustained contraction (SMVC). After each contraction series, there will be a 2-minute recovery period.
Statistical Analysis. Individual NIRS parameters for MPP subjects will be compared to controls by independent sample t-test or Wilcoxon signed-rank test. To generate a predictive model for MPP diagnosis, we will use Least Angle Shrinkage and Selection Operator (LASSO) to identify candidate predictors from individual NIRS features using ten-fold cross-validation. From potential predictors (i.e., non-zero coefficients), we will select features with standardized shrunken coefficients >0.4 to be used in a multivariable logistic regression model. Only statistically significant model coefficients will be retained to provide a reduced predictive model, whose performance will be evaluated by area under the receiver operating curve (AUROC). AUROC values >0.7 will be demonstrative of an acceptable diagnostic test. We will also report the sensitivity, specificity, and accuracy of the model to quantify anticipated impact.
Outcome: NIRS-based algorithm for the diagnosis of MPP. Impact: The R61 phase will validate vaginal NIRS as an effective, non-invasive, and scalable method to assess pelvic floor muscle fitness, correlating well with current measures of PFM strength and distinguishing the myofascial dysfunction associated with MPP from healthy controls.
Masking: None Allocation: Non-randomized
- Conditions
- Myofascial Pelvic Pain
- Being tested
- Pelvic Floor Muscle Assessment by Near-Infrared Spectroscopy
- Keywords
- pelvic pain
- Medical subject headings
- Pelvic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pelvic Floor Muscle Assessment by Near-Infrared SpectroscopyDiagnostic test
This study will develop and test an instrument to establish a normal range for near infrared spectroscopy (NIRS) optical changes associate with pelvic floor exercise in adult women based on the test-to test (intra-day) reliability of oxygen kinetics related to contraction of the pelvic floor muscle. We will establish the relationship between the quantitative NIRS data, the condition of Myofascial pelvic musculature and the symptomatology of MPP and related comorbidities. We will also evaluate prospectively the effectiveness of these data in predicting effective treatment modalities. Finally, we will optimize a training regime for non-specialists to allow this technique to be used in a variety of settings. The development of this device and validation of its relevance to diagnosis and treatment of MPP will provide effective care sooner and at a lower cost than current procedures. It will also reduce inequities in the availability of care to underserved populations.
| Study group | Role | What they receive |
|---|---|---|
| Control Subjects | Women age 18 or older without pelvic pain or other genitourinary complaints Receives: Diagnostic Test: Pelvic Floor Muscle Assessment by Near-Infrared Spectroscopy | |
| Myofascial Pelvic Pain Subjects | Women age 18 or older with pelvic floor muscle pain or tender points Receives: Diagnostic Test: Pelvic Floor Muscle Assessment by Near-Infrared Spectroscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
MPP Diagnosis
Accurate Diagnosis of Myofascial Pelvic Pain
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2025
- Study start23 Jan 2025
- Primary completion1 Jul 2026
- Study completion1 Sep 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myofascial Pelvic PainStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 110 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Collaborators
- National Center for Complementary and Integrative Health (NCCIH)
- Responsible party
- Principal investigator, Anne Lenore Ackerman, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07181447
- Sponsor's protocol ID
- 22-0428
- Other IDs
- R61AT013008-01
- Status last verified
- Sep 2025
- First submitted
- 11 Sep 2025
- Last updated
- 15 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: Once the study is completed, deidentified data will be submitted to a generalist repository that is supported by the BioMedical Informatics Coordinating Committee (BMIC) of the NIH, specifically the Harvard Dataverse open-source research data repository (https://dataverse.org).
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quantitative Assessment of Pelvic Floor Muscle Fitness in Myofascial Pelvic Pain
- ClinicalTrials.gov ID
- NCT07181447
- Acronym / sponsor ID
- 22-0428
- Conditions
- Myofascial Pelvic Pain
- Keywords
- pelvic pain
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 110 participants (actual)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Collaborators
- National Center for Complementary and Integrative Health (NCCIH)
- Study start
- 23 Jan 2025 (actual)
- Primary completion
- 1 Jul 2026 (actual)
- Study completion
- 1 Sep 2026 (actual)
- First posted
- 18 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Myofascial Pelvic Pain (MPP) is an often-misdiagnosed condition affecting up to 26% of women during their lives and imposing enormous costs on national health care systems. It frequently involves comorbidities such as bladder, bowel, and sexual dysfunction. There are no quantitative measures that adequately guide the physician and accurate diagnosis typically requires an internal examination by a tertiary specialist.
This study will develop and test an instrument to establish a normal range for near infrared spectroscopy (NIRS) optical changes associate with pelvic floor exercise in adult women based on the test-to test (intra-day) reliability of oxygen kinetics related to contraction of the pelvic floor muscle.
We will establish the relationship between the quantitative NIRS data, the condition of Myofascial pelvic musculature and the symptomatology of MPP and related comorbidities. We will also evaluate prospectively the effectiveness of these data in predicting effective treatment modalities. Finally, we will optimize a training regime for non-specialists to allow this technique to be used in a variety of settings.
The development of this device and validation of its relevance to diagnosis and treatment of MPP will provide effective care sooner and at a lower cost than current procedures. It will also reduce inequities in the availability of care to underserved populations by providing an inexpensive, reliable and easily available method for a variety of providers to address MPP.
Detailed description
DETAILED DESCRIPTION Introduction. Myofascial pelvic pain (MPP) is the predominant underlying cause in 60-90% of women with chronic pelvic pain. MPP can be debilitating, and is often associated with bladder, bowel, and sexual dysfunction. MPP can be debilitating, leading to social withdrawal, loss of productivity, impaired relationships, and psychological comorbidities. Despite the high prevalence, myofascial pain is often overlooked by first-line healthcare providers; most providers, including gynecologic and urologic specialists, lack the knowledge or experience to even identify MPP. Unfortunately, there are currently no widely accepted measures to quantify muscular fitness or dynamic function of the pelvic floor. Improved recognition of MPP needs objective, reproducible, and quantifiable assessments of PFM fitness, to differentiate between forms of myofascial dysfunction and correlate those patterns with different symptoms. Improved recognition of MPP needs objective, reproducible, and quantifiable assessments of PFM fitness, to facilitate improvements in the recognition and diagnosis of MPP.
Objective: This trial will use optical technology (near infrared spectroscopy) to provide novel imaging and physiologic measures relevant to the PFM for the diagnostic evaluation of MPP.
Primary Purpose: Diagnostics Subject Recruitment: Healthy controls, who must lack pelvic pain, bowel disturbances, urinary symptoms, or sexual dysfunction, will be recruited from the community through online and targeted advertisements in gynecology and primary clinics. IRB approval for these studies is already in place, and we have already begun recruitment of control volunteers. Subjects with MPP, defined by pelvic floor myofascial pain in the absence of other identifiable pain generators, will be recruited from the UCLA Center for Women's Pelvic Health.24 MPP subjects meeting inclusion/exclusion criteria will be approached for enrollment prior to treatment assignment. Baseline demographics and clinical data, including age, height, weight, comorbidities, past surgeries, and medications, including hormones, will be self-reported at enrollment through a questionnaire on REDCap.
Vaginal NIRS-based Pelvic Floor Assessment: An 8-channel, multipoint vaginal NIRS interface miniaturized into a tampon-sized instrument, capable of measuring regional changes in pelvic floor muscle oxygenation in different quadrants and muscle depths, will assess oxygenation and hemodynamic parameters in the pelvic floor muscles. The NIRS sensor, housed in a sterile, single use, disposable child size speculum and placed within a sterile cover, will be inserted in the vagina. The participant will then complete two rounds of the same standardized series of contractions: a series of three maximal voluntary contractions (MVC) and one sustained contraction (SMVC). After each contraction series, there will be a 2-minute recovery period.
Statistical Analysis. Individual NIRS parameters for MPP subjects will be compared to controls by independent sample t-test or Wilcoxon signed-rank test. To generate a predictive model for MPP diagnosis, we will use Least Angle Shrinkage and Selection Operator (LASSO) to identify candidate predictors from individual NIRS features using ten-fold cross-validation. From potential predictors (i.e., non-zero coefficients), we will select features with standardized shrunken coefficients >0.4 to be used in a multivariable logistic regression model. Only statistically significant model coefficients will be retained to provide a reduced predictive model, whose performance will be evaluated by area under the receiver operating curve (AUROC). AUROC values >0.7 will be demonstrative of an acceptable diagnostic test. We will also report the sensitivity, specificity, and accuracy of the model to quantify anticipated impact.
Outcome: NIRS-based algorithm for the diagnosis of MPP. Impact: The R61 phase will validate vaginal NIRS as an effective, non-invasive, and scalable method to assess pelvic floor muscle fitness, correlating well with current measures of PFM strength and distinguishing the myofascial dysfunction associated with MPP from healthy controls.
Masking: None Allocation: Non-randomized
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control Subjects | – | Diagnostic Test: Pelvic Floor Muscle Assessment by Near-Infrared SpectroscopyWomen age 18 or older without pelvic pain or other genitourinary complaints |
| Myofascial Pelvic Pain Subjects | – | Diagnostic Test: Pelvic Floor Muscle Assessment by Near-Infrared SpectroscopyWomen age 18 or older with pelvic floor muscle pain or tender points |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The control subjects (cohort 1) will be adult 18 (>18 years of age) who lack pelvic pain or other genitourinary symptoms. The MPP cohort (cohort 2) will consist of adult women >18 years of age with pelvic floor muscle pain or tender points.
Key inclusion criteria (5 listed)
- Women between 18 and 100 years of age
- Pelvic pain for more than 6 months duration
- Report an average daily pain intensity score of at least 4 (on a 0 to 10 scale)
- Palpable trigger/tender points in internal pelvic floor muscles on standardized myofascial pelvic floor exam
- Willing to refrain from new clinical treatments that may affect pain during the study period
Key exclusion criteria (11 listed)
- Inability to participate in clinic visits
- Prior invasive pelvic procedures for pain (e.g., prior pelvic surgery, sacral neuromodulation, intradetrusor Botox®)
- Active UTI or vaginal infection
- Pregnancy, childbirth during the previous 12 months, currently planning pregnancy
- Illicit Drug addiction/regular use of controlled substances
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pelvic Floor Muscle Assessment by Near-Infrared SpectroscopyThis study will develop and test an instrument to establish a normal range for near infrared spectroscopy (NIRS) optical changes associate with pelvic floor exercise in adult women based on the test-to test (intra-day) reliability of oxygen kinetics related to contraction of the pelvic floor muscle. We will establish the relationship between the quantitative NIRS data, the condition of Myofascial pelvic musculature and the symptomatology of MPP and related comorbidities. We will also evaluate prospectively the effectiveness of these data in predicting effective treatment modalities. Finally, we will optimize a training regime for non-specialists to allow this technique to be used in a variety of settings. The development of this device and validation of its relevance to diagnosis and treatment of MPP will provide effective care sooner and at a lower cost than current procedures. It will also reduce inequities in the availability of care to underserved populations. | Diagnostic test | Control Subjects, Myofascial Pelvic Pain Subjects |
Primary outcome
MPP Diagnosis
Time frame: 1 day
Accurate Diagnosis of Myofascial Pelvic Pain
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2026.
- Individual participant dataSharing planned: Yes. Once the study is completed, deidentified data will be submitted to a generalist repository that is supported by the BioMedical Informatics Coordinating Committee (BMIC) of the NIH, specifically the Harvard Dataverse open-source research data repository (https://dataverse.org).
Related trials for Myofascial Pelvic Pain
Not yet recruiting
Measuring Pelvic Floor Muscle Fitness Before and After Treatment
Myofacial Pain, Pelvic Pain
Recruiting
Transvaginal Electrical Stimulation for Myofascial Pelvic Pain
Myofascial Pelvic Pain
Enrolling by invitationObservational study
Bruxism, Pelvic Pain, Erectile Dysfunction, and Anxiety in Young Adult Men
Bruxism, Pelvic Pain
Enrolling by invitationObservational study
Bruxism and Pelvic Floor Dysfunction in Young Women
Bruxism, Pelvic Floor Disorder
Recruiting
Effects of PEMM in Chronic Low Back Pain Women With Urinary Incontinence
Chronic Low-back Pain (cLBP), Urinary Incontinence (UI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myofascial Pelvic Pain, run by University of California, Los Angeles at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MPP Diagnosis (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026; AzTrials last refreshed its copy on 8 Nov 2026.